Minimal Residual Disease (MRD) Testing
News and reporting on minimal residual disease testing.
New Study Results Boost Evidence for Natera's MRD Assays to Guide Adjuvant Therapy Decisions
Premium
The data, from a large prospective cohort, support the value of chemotherapy for ctDNA-positive patients, regardless of clinical stage.
Geneseeq Nabs CE Marks for Residual Disease and Cancer Early Detection Tests
The MRD assay uses deep sequencing to detect cancer mutations in blood post-surgery and the early detection test involves multiomic analysis of cell-free DNA.
Invitae Bets on Oncology Portfolio to Drive Growth as it Streamlines, Integrates Test Services
Premium
In the wake of last year's massive restructuring, Invitae is focused on developing its Personalized Cancer Monitoring product while integrating other oncology offerings.
Guardant Health, Royal Marsden Partner on Prospective Liquid Biopsy Trial in Early Colorectal Cancer
The study is evaluating the Guardant Reveal assay to guide chemotherapy treatment decisions following surgery for stage II to III colorectal cancer.
Natera Files Second Patent Infringement Suit Against NeoGenomics Subsidiary Inivata
The suit was filed the same day Natera received a new patent covering its patient-specific residual cancer testing and monitoring methods.